

Potential Risks of OTC Pravachol 10mg

■ Safety

- Extensively characterized: > 20 million patient years Rx use and > 100,000 patient years in clinical trials
- Safety risk is minimal and conveyed on label

■ Potential for Distraction

- Market research indicates majority will discuss with physician
- Consumer use studies: subjects rarely shifted from Rx to OTC
- Substantial number brought into prescription therapy after dialogue with physician

AA-5-3

Potential Benefits of OTC Pravachol 10mg

■ Increased utilization

- Rapid enrollment in PREDICT and OPTIONS confirms interest
- People looking for self care options:
~ twice as many using non-Rx therapies vs Rx medications to lower cholesterol

■ Meaningful LDL-C reduction

- ~18% reduction in LDL-C demonstrated in OTC environment over time; > 80% achieve NCEP goal

■ Significant numbers brought into health care system

■ Long term benefit

- Program has potential to treat major modifiable CHD risk factor

AA-5-4


Conclusion

- Pravachol 10 has a safety profile that is appropriate for OTC status
- Pravachol 10 provides meaningful LDL-C reduction
- The proposed program and labeling will result in more people on appropriate treatment
- OTC Pravachol 10 is an appropriate option for lower risk individuals choosing to lower their cholesterol and provides a complementary additional approach to current efforts

AA-5-5


AA-5-8

PREDICT Extension: OTC Compliance Maintained at 1 Year



AA-3-28

PREDICT Extension Reduction in LDL-C Maintained at 1 Year (Extension Population)



AA-3-29

5-July-00